Cargando…

Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review

There have been several episodes of viral infection evolving into epidemics in recent decades, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the latest example. Its high infectivity and moderate mortality have resulted in an urgent need to find an effective treatment modality....

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Y. C., Tsai, T. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	When Rheumatology and Infectious Disease Come Together
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476354/ https://www.ncbi.nlm.nih.gov/pubmed/32952617 http://dx.doi.org/10.1177/1759720X20947296

Ejemplares similares

Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents
por: Fernandez-Gutierrez, Benjamin, et al.
Publicado: (2021)

JAK inhibitors and infections risk: focus on herpes zoster
por: Sunzini, Flavia, et al.
Publicado: (2020)

Factors associated with sepsis risk in immune-mediated inflammatory diseases receiving tumor necrosis factor inhibitors: a nationwide study
por: Chao, Wen-Cheng, et al.
Publicado: (2020)

Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
por: Evangelatos, Gerasimos, et al.
Publicado: (2020)

Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations
por: Koutsianas, Christos, et al.
Publicado: (2020)

Hidradenitis suppurativa: infection, autoimmunity, or both?
por: Constantinou, Costas A, et al.
Publicado: (2019)

A cross-sectional investigation into the association between Porphyromonas gingivalis and autoantibodies to citrullinated proteins in a German population
por: Oluwagbemigun, Kolade, et al.
Publicado: (2019)

Mortality risk prediction in lupus patients complicated with invasive infection in the emergency department: LUPHAS score
por: Wu, Wanlong, et al.
Publicado: (2019)

Evaluation of Access Disparities to Biologic Disease-Modifying Antirheumatic Drugs in Rural and Urban Communities
por: Peterman, Nicholas J, et al.
Publicado: (2022)

Do biological disease-modifying antirheumatic drugs reduce the spinal fracture risk related to ankylosing spondylitis? A longitudinal multiregistry matched cohort study
por: Robinson, Yohan, et al.
Publicado: (2017)

Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland
por: Burkard, Theresa, et al.
Publicado: (2022)

A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers
por: Ng, Bernard, et al.
Publicado: (2013)

Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
por: Uhrenholt, Line, et al.
Publicado: (2019)

Association of biological antirheumatic therapy with risk for type 2 diabetes: a retrospective cohort study in incident rheumatoid arthritis
por: Paul, Sanjoy K, et al.
Publicado: (2021)

Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case–control study in Asia
por: Liao, Tsai-Ling, et al.
Publicado: (2017)

Antiviral Activity of Svarnvir-IV Tablet Assayed for Activity Against SARS-CoV-2 In Vitro
por: Reddy, K. Ramachandra, et al.
Publicado: (2023)

Effect of a 12-week high-intensity exercise intervention: a comparison of cardiac exercise adaptations during biological disease-modifying antirheumatic drug treatment (TNF inhibitors vs IL-6 signalling inhibitors) in patients with rheumatoid arthritis – study protocol for a randomised controlled trial
por: Jønck, Simon, et al.
Publicado: (2023)

Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis
por: Huang, Bin, et al.
Publicado: (2020)

Coming Events
Publicado: (1899)

Experience of an Orthopaedic Surgery Department Early During the COVID-19 Outbreak in Japan Including Real-Time Polymerase Chain Reaction Assay Results for SARS-CoV-2
por: Inoue, Gen, et al.
Publicado: (2020)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh
por: Hasan, Md Jahidul, et al.
Publicado: (2022)

Possible Links between Intestinal Permeablity and Food Processing: A Potential Therapeutic Niche for Glutamine
por: Rapin, Jean Robert, et al.
Publicado: (2010)

Antirheumatic drugs and reproduction in women and men with chronic arthritis
por: Bazzani, Chiara, et al.
Publicado: (2015)

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)
por: Abhishek, Abhishek, et al.
Publicado: (2022)

Does Fecal-Oral Transmission of SARS-CoV-2 Due to Low Sanitation Conditions Contribute to Low Mortality Rates From COVID-19
por: Rothschild, Nathan
Publicado: (2021)

Radiographic findings of SARS‐CoV‐2 infection
por: Marco, Catherine A., et al.
Publicado: (2021)

A multicentre observational study on neonates exposed to SARS-CoV-2 in China: the Neo-SARS-CoV-2 Study protocol
por: Xiao, Tiantian, et al.
Publicado: (2020)

Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort
por: White, Douglas, et al.
Publicado: (2013)

SARS-CoV-2 Seroprevalence at an Urban Hospital in Haiti
por: Price, Robert, et al.
Publicado: (2022)

Immunosuppression and Opportunistic Infections: A Rare Case Report of Nocardia Osteomyelitis of the Pelvis
por: Suarez, Richard I, et al.
Publicado: (2023)

Factors associated with non-persistence to oral and inhaled antiviral therapies for seasonal influenza: a secondary analysis of a double-blind, multicentre, randomised clinical trial
por: Flicoteaux, Remi, et al.
Publicado: (2017)

Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
por: Hsieh, Cho-Hsun, et al.
Publicado: (2022)

Evolutionary Perspective and Theories on the Possible Origin of SARS-CoV-2
por: Saeed, Amanj A
Publicado: (2021)

Attenuation and Degeneration of SARS-CoV-2 Despite Adaptive Evolution
por: Liu, Yingguang
Publicado: (2023)

Two-Hit Kidney Allograft Injury by SARS-CoV-2
por: Ribeiro, Bárbara, et al.
Publicado: (2023)

Environmental Contamination With SARS-CoV-2 in a Hospital Setting
por: Kumar, Sumit, et al.
Publicado: (2023)

An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment
por: Arishi, Naif A, et al.
Publicado: (2023)

Community-Based Seroprevelance of SARS-CoV-2 in Saudi Arabia
por: Alassaf, Lujain, et al.
Publicado: (2022)

Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
por: Yahav, Dafna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cs71rnmjdqia73q4bqrqvpeh5i